{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T14:02:21Z","timestamp":1792332141374,"version":"4.4.0"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1097\/mph.0b013e31802d3e2d","type":"journal-article","created":{"date-parts":[[2006,12,12]],"date-time":"2006-12-12T18:30:29Z","timestamp":1165948229000},"page":"837-839","source":"Crossref","is-referenced-by-count":13,"title":["Flushing Out of Cerebrospinal Fluid as a Therapy for Acute Cerebellar Dysfunction Caused by High Dose of Cytosine Arabinoside: A Case Report"],"prefix":"10.1097","volume":"28","author":[{"given":"Isabelle","family":"Pellier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Leboucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petronela","family":"Rachieru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Ifrah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Rialland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20210227","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1200\/JCO.1985.3.5.613","article-title":"Cerebellar toxicity following high-dose cytosine arabinoside","volume":"3","author":"Dworking","year":"1985","journal-title":"J Clin Oncol"},{"key":"R2-14-20210227","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1200\/JCO.1991.9.4.679","article-title":"Cytarabine and neurologic toxicity","volume":"9","author":"Baker","year":"1991","journal-title":"J Clin Oncol"},{"key":"R3-14-20210227","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1200\/JCO.1987.5.6.927","article-title":"Cereballar toxicity with high-dose cytosine arabinoside","volume":"5","author":"Herzig","year":"1987","journal-title":"J Clin Oncol"},{"key":"R4-14-20210227","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/mpo.2950190210","article-title":"Bulbar and pseudobulbar palsy complicating therapy with high-dose cytosine arabinoside in children with leukemia","volume":"19","author":"Shaw","year":"1991","journal-title":"Med Pediatr Oncol"},{"key":"R5-14-20210227","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/BF00689281","article-title":"Cerebellar toxicity during cytarabine therapy associated with renal insufficiency","volume":"27","author":"Hasle","year":"1990","journal-title":"Cancer Chemother Pharmacol"},{"key":"R6-14-20210227","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1093\/jnci\/84.7.500","article-title":"Clustering of adverse drug events: analysis of risk factors for cerebellar toxicity with high-dose cytarabine","volume":"84","author":"Jolson","year":"1992","journal-title":"J Natl Cancer Inst"},{"key":"R7-14-20210227","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/ajh.20171","article-title":"Cytarabine-induced neurotoxicity responding to methyl-prednisolone","volume":"77","author":"Pankaj","year":"2004","journal-title":"Am J Hematol"},{"key":"R8-14-20210227","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/1097-0142(19830201)51:3<426::AID-CNCR2820510312>3.0.CO;2-S","article-title":"Acute cerebellar dysfunction with high-dose ARA-C therapy","volume":"51","author":"Salinsky","year":"1983","journal-title":"Cancer"},{"key":"R9-14-20210227","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2165\/00002018-199005010-00003","article-title":"The toxicity of cytarabine","volume":"5","author":"Stentoft","year":"1990","journal-title":"Drug Safety"},{"key":"R10-14-20210227","first-page":"4141","article-title":"Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosyluracil following the repeated intravenous administration of high and intermediate-dose 1-beta-D-arabinofuranosylcytosine","volume":"51","author":"Damon","year":"1991","journal-title":"Cancer Res"},{"key":"R11-14-20210227","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1200\/JCO.1992.10.6.948","article-title":"Risk factors for high-dose cytarabine neurotoxicity: an analysis of cancer and leukemia group B trial in patients with acute myeloid leukemia","volume":"10","author":"Rubin","year":"1992","journal-title":"J Clin Oncol"},{"key":"R12-14-20210227","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1200\/JCO.1997.15.2.833","article-title":"High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency","volume":"15","author":"Smith","year":"1997","journal-title":"J Clin Oncol"},{"key":"R13-14-20210227","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1038\/sj.leu.2403920","article-title":"Treatment strategies and long-term results in pediatric patients treated in four consecutive AML-BFM trials","volume":"19","author":"Creutzig","year":"2005","journal-title":"Leukemia"},{"key":"R14-14-20210227","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1038\/sj.leu.2403925","article-title":"Long-term results of children with acute myeloid leukemia: a report of three consecutive phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891","volume":"19","author":"Smith","year":"2005","journal-title":"Leukemia"},{"key":"R15-14-20210227","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1038\/sj.leu.2403867","article-title":"Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit\u2014multicenter studies of the French LAME (Leucemie Aig\u00fce Myeloblastique Enfant) Cooperative Group","volume":"19","author":"Perel","year":"2005","journal-title":"Leukemia"},{"key":"R16-14-20210227","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.0954-6820.1988.tb16760.x","article-title":"Severe persistent cerebellar dysfunction complicating cytosine arabinoside therapy","volume":"224","author":"Boesen","year":"1988","journal-title":"Acta Med Scand"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MPH.0b013e31802d3e2d","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:18:15Z","timestamp":1786033095000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00043426-200612000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":16,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0b013e31802d3e2d","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2006,12]]}}}